In Brief: Royce Labs
Royce Labs: Company and CEO Patrick McEnany enter settlement with the SEC resolving an investigation into Royce's disclosure between July 1991 and April 1992 regarding the status of its ANDAs for piroxicam and minoxidil and on sales of company securities during that time. Royce and McEnany consented to a civil injunction requiring them to comply with securities laws in the future. McEnany paid a $25,000 administrative fine that was reimbursed to him by the company...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth